## **Open Access**

# Correction to: Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature



G. A. Taarnhøj<sup>1</sup>, C. Johansen<sup>1,2</sup> and H. Pappot<sup>1\*</sup>

### Correction to: Health Qual Life Outcomes (2019);17:20 https://doi.org/10.1186/s12955-018-1077-6

The original article [1] contains a major error whereby a main Table is omitted. Thus, new Table 3 (shown ahead) should be considered as Table 3 in the original article. All citations in the text to tables are with these changes are correct.

#### Author details

<sup>1</sup>Department of Oncology, Rigshospitalet, Blegdamsvej 9, section 5073, 2100 Copenhagen Ø, Denmark. <sup>2</sup>Unit of Survivorship, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen Ø, Denmark.

#### Published online: 23 January 2020

#### Reference

 Taarnhøj GA, Johansen C, Pappot H. Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature. Health Qual Life Outcomes. 2019;17:20. https://doi.org/10.1186/ s12955-018-1077-6.

The original article can be found online at https://doi.org/10.1186/s12955-018-1077-6

\* Correspondence: helle.pappot@regionh.dk

 $^1\text{Department}$  of Oncology, Rigshospitalet, Blegdamsvej 9, section 5073, 2100 Copenhagen Ø, Denmark

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

#### Table 3 Outcome: Overall QoL

		GRADE issues					Overall GRADE rating
	Nb. of studies	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	
Before diagnosis	1 [12]	X <sup>1</sup>		X <sup>2</sup>	X <sup>3</sup>		0 0 0 0 0 0 0 0
Before treatment	4 [14, 18-19, 27]		X <sup>4</sup> , X <sup>5</sup>				$\oplus \oplus \oplus \oplus$
During treatment	2 [16, 18]		X <sup>4</sup>	X <sup>6</sup>	X <sup>3</sup>		$\bigoplus \oplus \oplus \oplus$
≤ 6 months after treatment	4 [18-19, 27, 34]	X <sup>7</sup>	X <sup>5</sup>				$\bigoplus \bigoplus \bigoplus \bigoplus$
> 6 months after treatment	7 [13, 20-21, 24-25, 27, 35]	X <sup>8</sup>	X <sup>9</sup> , X <sup>5</sup>			None apparent <sup>10</sup>	$\bigoplus \bigoplus \bigoplus \bigoplus$

<sup>1</sup> Two validated QoL questionnaires with very large difference between outcomes <sup>2</sup> Predominantly NMIBC patients, scores not specific for MIBC population

<sup>3</sup> Small number of patients

<sup>4</sup> Large difference in populations hence diverging scores

<sup>5</sup> Use of different QoL scales

<sup>6</sup> Only one study representing metastatic population, no studies representing neoadjuvant population
<sup>7</sup> Mixed BC population, selected population [34]

<sup>8</sup> Compliance 47-77%, thereby introducing selection bias

<sup>9</sup> QoL questionnaires designed for prostate population

<sup>10</sup> As estimated by funnel plot